Lupin achieves S&P Global ESG score of 91

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth

Kaiser Permanente’s study highlights power of genetics in preventing heart disease

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD

BASF and Beyond Suncare welcome WHO decision to list broad-spectrum sunscreen as “Essential Medicine”

The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance

Trump clinches historic deal as Lilly, Novo slash U.S. weight-loss drug prices

Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans

AstraZeneca invests additional $136 million to expand Qingdao inhalants facility

This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

Merck advances cancer innovation by expanding role of Keytruda across new tumor

The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price

Biocon Biologics’ retinal disorder medication Yesafili gets public funding in Canada

Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada

Biocon Foundation launches BioWISE Program to empower women in STEM

25 women students to receive internship, training, and mentorship in Life Sciences segment